TORONTO, Oct. 26, 2023 /CNW/ - Medical Facilities Corporation (TSX: DR) ("Medical Facilities" or "MFC") will release its third quarter 2023 financial results prior to market open on Thursday, November 9, 2023. MFC's financial statements and management's discussion and analysis for the three-month period ended September 30, 2023 will be filed on SEDAR+ at www.sedarplus.ca following the release, and will be available on the same day on MFC's website at www.medicalfacilitiescorp.ca. Management will host an earnings conference call to review the financial results at 8:30 a.m. ET the same morning.
Interested parties may join the conference call by dialing 1-877-550-1875 approximately 15 minutes prior to the call to secure a line. You will be put on hold until the conference call begins. A question-and-answer session will follow management's prepared remarks, at which time the operator will provide instructions to qualified equity analysts for submitting questions.
A live audio webcast of the call will be available at https://bit.ly/MFC2023Q3. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived on MFC's website following the call date.
Medical Facilities, in partnership with physicians, owns a diverse portfolio of highly rated, high-quality surgical facilities in the United States. MFC's ownership includes controlling interest in four specialty surgical hospitals located in Arkansas, Oklahoma, and South Dakota, and an ambulatory surgery center ("ASC") located in California. The specialty surgical hospitals perform scheduled surgical, imaging, diagnostic and other procedures, including primary and urgent care, and derive their revenue from the fees charged for the use of their facilities. The ASC specializes in outpatient surgical procedures, with patient stays of less than 24 hours. For more information, please visit www.medicalfacilitiescorp.ca.
Last Trade: | C$15.26 |
Daily Change: | -0.34 -2.18 |
Daily Volume: | 29,557 |
Market Cap: | C$357.080M |
March 03, 2025 November 07, 2024 August 06, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load